Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-27
2007-02-27
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300, C530S330000, C530S331000, C548S146000, C548S215000
Reexamination Certificate
active
10403542
ABSTRACT:
The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
REFERENCES:
patent: 4977153 (1990-12-01), Louis et al.
patent: 5439906 (1995-08-01), Bock et al.
patent: 5530026 (1996-06-01), Gaudreault et al.
patent: 6017890 (2000-01-01), Hoekstra et al.
patent: 2011222 (1990-03-01), None
patent: 0 385 850 (1990-09-01), None
patent: WO 92/14750 (1992-09-01), None
patent: WO 93/18026 (1993-09-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/33798 (1999-07-01), None
patent: WO 99/42475 (1999-08-01), None
Linde et al, “Pharmacological treatment for prevention of restenosis” Expert Opinion, 2001, pp. 281-302, Ashley Publications, www.ashley-pub.com, Canada.
Ischinger, Thomas, “Antithrombotics in Interventional Cardiology: Optimizing Treatment and Strategies”, 1998, pp. 25L-28L, vol. 28 (5B), Excerpta Medica, Inc., The American Journal of Cardiology.
Schwartz, Robert, “Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling”, Excerpta Medica, Inc., A Symposium: Interventional Vascular Medicine, 1998, pp. 14E-17E.
Marx et al, “Rampamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells” Circulation Research, 1995 American Heart Association, Inc. 1995, vol. 76, pp. 412-417.
Sollott et al, “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty In the Rat” The Journal of Clinical Investigation, Inc., Apr. 1995, pp. 1869-1876, The Journal of Clinical Investigation, Inc., vol. 95, pp. 1869-1876.
Suzuki et al, “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model” 2001 American Heart Association, pp. 1188-1193, USA.
Andrade-Gordon et al, “Adminstration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats” , The Journal of Pharmacology and Experimental Therapeutics, 2001, 298: No. 1, pp. 34-42, USA.
Derian, Claudia et al, “Blockage of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Non-Human Primates” The Journal of Pharmacology and Experimental Therapeutics 2003, pp. 855-861, vol. 304, The American Society of Pharmacology and Experiemental Therapeutics.
Chesebro et al, “Antithrombotic Therapy and Progression of Coronary Artery Disease, Antiplatelet vs. Antithrombins”, Circulation, 1992, 86[suppl III]: III-100-III-111.
White, Harvey, “Newer Antiplatelet Agents in Acute Coronary Syndromes” Cardiology Dept. Green Lane Hospital, New Zealand, e-mail: harveyw@ahsl.co.nz, 1999, Mosby, Inc.
Verstraete et al, “Novel Antithrombotic Drugs in Development”, Center for Molecular and Vascular Biology, University of Leuven, Belgium, Drugs, 1995, pp. 856-884, Adis International Limited.
Weksler, Babette, “Antiplatelet Agents in Stroke Prevention” Dept. of Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journal/ced.
Mousa, Shaker, “Antiplatelet Therapies: From Aspirin to GPIIb/IIIa-Receptor Antagonists and Beyond” Therapeutic Focus, Elsevier Science LTD, 1999, pp. 552-560, vol. 4, No. 12, USA.
U.S. Appl. No. 09/603,229, McComsey et al.
U.S. Appl. No. 09/599,826, Zhang et al.
U.S. Appl. No. 09/603,338, Zhang et al.
PCT Search Report for corresponding PCT application (PCT/US 00/18018) dated Nov. 10, 2000.
“Cloning and Characterization of Human Protease-Activated Receptor 4”, Wen-Feng Xu et al., Proc. Natl. Acad. Sci. USA, vol. 95, Jun. 1998, pp. 6642-6646.
“Molecular Cloning of a Potential Proteinase Activated Receptor”, Swerker Nystedt et al., Proc. Natl. Acad Sci. USA, vol. 91, Sep. 1994, pp. 9208-9212.
“Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor”, David T. Hung, et al., The Journal of Cell Biology, vol. 116, No. 3, Feb. 1992, pp. 827-832.
Thrombin Receptor Activation Causes Rapid Neural Cell Rounding and Neurite Retraction Independent of Classic Second Messengers, Kees Jalink et al., The Journal of Cell Biology, vol. 118, No. 2, Jul. 1992, pp. 411-419.
“Thrombin-Induced Expression of Endothelial P-Selectin and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion”, Yasuo Sugama et al., The Journal of Cell Biology, vol. 119, No. 4, Nov. 1992, pp. 935-944
“Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, Thien-Khal H. Vu et al., Cell, vol. 64, Mar. 1991, pp. 1057-1068.
“Response of a Human Megakaryocytic Cell Line To Thrombin: Increase in Intracellular Free Calcium and Mitogen Release”, Cindy L. A. Jones, et al., Biochemica et Bioophysica Acta. 1136, 1992, pp. 272-282.
“Thrombin Effects on Osteoblastic Cells—II. Structure-Function Relationships” Dimitris N. Tatalkis et al., Biochemical and Biophysical Research Communications, vol. 174, No. 1, Jan. 1991, pp. 181-188.
“Condensed Heteroaromatic Ring Systems—XIII. One-Step Synthesis of 2-Substituted 1-Methylsulfoonylindoles from N-(2-Halophenyl) Methanesulfonamides”, Takao Sakamoto et al., Chem. Pharm. Bull., No. 4, Sep. 1987, pp. 1305-1308.
“An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey”, Jacquelynn J. Cook et al., Basic Science Reports, Oct. 1994, pp. 2961-2971.
“Protease-Activated Receptor 3 is a Second Thrombin Receptor in Humans”, Hiroald Ishihara, Nature, vol. 386, Apr. 1997, pp. 502-508.
“Heterocycle-Peptide Hybrid Compounds, Aminotriazole-Containing Agonists of the Thrombin Receptor (Par-1)”, David F. McComsey et al., Bioorganic & Medicinal Chemistry Letters 9 (1999), pp. 1423-1428.
“Design, Synthesis, and Biological Characterization of a Peptide-Mimetic Antagonist for a Tethered-Ligand Receptor”, Patricia Andrade-Gordon et al., PNAS, vol. 96, No. 22, Oct. 26, 1999, pp. 12257-12262.
Thrombin Receptor (PAR-1) Antagoonists, Heterocycle-Based Peptidomimetics of the SFLLR Agonist MOTIF, William J. Hoekstra et al., Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1649-1654.
“Development of Potent Thrombin Receptor Antagonist Peptides”, Michael S. Bernatowicz et al., J. Med. Chem., 1996, vol. 39, No. 25, pp. 4879-4887.
“Design, Synthesis, and Structure-Activity Relationship for a Series of Factor XA Inhibitors Containing The Benzimidazoone Nucleus as a Central Template”, Charles K. Marlowe et al., Medicinal Chemistry, COR Therapeutics, Inc., Abstract.
“Novel Indole-based Peptidomimetics as Potent Thrombin Receptor (PAR-1) Antagonists”, Han Chen Zheng et al., The R.W. Johnson Pharmaceutical Research Institute, Abstract.
“Approaches to the Synthesis of Ureapeptoid Peptidomimetics”, John A. W. Kruijtzer et al., Tetrahedron Letters, vol. 38, No. 30, pp. 5335-5338, 1997.
Hoekstra William J.
Maryanoff Bruce E.
McComsey David F.
Zhang Han-Cheng
Ortho-McNeil Pharmaceutical , Inc.
Saeed Kamal A.
Stercho Yuriy
LandOfFree
Indole peptidomimetics as thrombin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole peptidomimetics as thrombin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole peptidomimetics as thrombin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3849054